PURPOSE: We investigated the efficacy of hyperbaric oxygen therapy (HBOT) in the management of patients with radiation-induced late side effects, the majority of whom had failed previous interventions. METHODS AND MATERIALS: Of 105 eligible subjects, 30 had either died or were not contactable, leaving 75 who qualified for inclusion in this retrospective study. Patients answered a questionnaire documenting symptom severity before and after treatment (using Radiation Therapy Oncology Group criteria), duration of improvement, relapse incidence, and HBOT-related complications. RESULTS: The rate of participation was 60% (45/75). Improvement of principal presenting symptoms after HBOT was noted in 75% of head-and-neck, 100% of pelvic, and 57% of "other" subjects (median duration of response of 62, 72, and 68 weeks, respectively). Bone and bladder symptoms were most likely to benefit from HBOT (response rate, 81% and 83%, respectively). Fifty percent of subjects with soft tissue necrosis/mucous membrane side effects improved with HBOT. The low response rate of salivary (11%), neurologic (17%), laryngeal (17%), and upper gastrointestinal symptoms (22%) indicates that these were more resistant to HBOT. Relapse incidence was low (22%), and minor HBOT-related complications occurred in 31% of patients. CONCLUSION: Hyperbaric oxygen therapy is a safe and effective treatment modality offering durable relief in the management of radiation-induced osteoradionecrosis either alone or as an adjunctive treatment. Radiation soft tissue necrosis, cystitis, and proctitis also seemed to benefit from HBOT, but the present study did not have sufficient numbers to reliably predict long-term response.
PURPOSE: We investigated the efficacy of hyperbaric oxygen therapy (HBOT) in the management of patients with radiation-induced late side effects, the majority of whom had failed previous interventions. METHODS AND MATERIALS: Of 105 eligible subjects, 30 had either died or were not contactable, leaving 75 who qualified for inclusion in this retrospective study. Patients answered a questionnaire documenting symptom severity before and after treatment (using Radiation Therapy Oncology Group criteria), duration of improvement, relapse incidence, and HBOT-related complications. RESULTS: The rate of participation was 60% (45/75). Improvement of principal presenting symptoms after HBOT was noted in 75% of head-and-neck, 100% of pelvic, and 57% of "other" subjects (median duration of response of 62, 72, and 68 weeks, respectively). Bone and bladder symptoms were most likely to benefit from HBOT (response rate, 81% and 83%, respectively). Fifty percent of subjects with soft tissue necrosis/mucous membrane side effects improved with HBOT. The low response rate of salivary (11%), neurologic (17%), laryngeal (17%), and upper gastrointestinal symptoms (22%) indicates that these were more resistant to HBOT. Relapse incidence was low (22%), and minor HBOT-related complications occurred in 31% of patients. CONCLUSION: Hyperbaric oxygen therapy is a safe and effective treatment modality offering durable relief in the management of radiation-induced osteoradionecrosis either alone or as an adjunctive treatment. Radiation soft tissue necrosis, cystitis, and proctitis also seemed to benefit from HBOT, but the present study did not have sufficient numbers to reliably predict long-term response.
Authors: Chong Duan; Carlos J Perez-Torres; Liya Yuan; John A Engelbach; Scott C Beeman; Christina I Tsien; Keith M Rich; Robert E Schmidt; Joseph J H Ackerman; Joel R Garbow Journal: J Neurooncol Date: 2017-04-19 Impact factor: 4.130
Authors: P Craighead; M A Shea-Budgell; J Nation; R Esmail; A W Evans; M Parliament; T K Oliver; N A Hagen Journal: Curr Oncol Date: 2011-10 Impact factor: 3.677
Authors: Rachel J Gibson; Dorothy M K Keefe; Rajesh V Lalla; Emma Bateman; Nicole Blijlevens; Margot Fijlstra; Emily E King; Andrea M Stringer; Walter J F M van der Velden; Roger Yazbeck; Sharon Elad; Joanne M Bowen Journal: Support Care Cancer Date: 2012-11-10 Impact factor: 3.603
Authors: Xiaoyu Jiang; Carlos J Perez-Torres; Dinesh Thotala; John A Engelbach; Liya Yuan; Jeremy Cates; Feng Gao; Robert E Drzymala; Keith M Rich; Robert E Schmidt; Joseph J H Ackerman; Dennis E Hallahan; Joel R Garbow Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-15 Impact factor: 7.038